{"success":true,"data":{"pressRelease":{"id":"154736","rtpr_id":"nGNE6ThVP3-20260929","ticker":"PHAR","exchange":"Euronext Amsterdam","all_tickers":["PHAR"],"title":"REG-Pharming announces CEO transition","author":"Globe Newswire","published_at":"2026-09-29T05:00:00.176Z","article_body":"Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam:\nPHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune\nand genetic diseases, today announced that the Board of Directors and Fabrice\nChouraqui have mutually agreed that Mr. Chouraqui will step down as Chief\nExecutive Officer and Executive Director, with immediate effect.\n\nTo ensure continuity of leadership, the Board of Directors has appointed Mrs.\nLeverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief\nFinancial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will\nlead the patient-focused operations while Mr. Lynard will lead the global\ncorporate functions. The Board has started a formal search for a permanent\nsuccessor.\n\nFollowing discussions about the execution of Pharming's strategic priorities\nfor the next phase of the company, the Board of Directors and Mr. Chouraqui\nhave concluded that their views on how to advance the company's strategy are\nnot sufficiently aligned. In good consultation, the parties have therefore\nagreed on a leadership transition.\n\nPharming’s strategy, pipeline and commitment to patients remain unchanged.\nFocus remains on executing the strategic priorities and advancing the next\nphase of growth.\n\n“On behalf of the Board, I would like to express our appreciation for Mr.\nChouraqui’s contributions. We wish him well on his next endeavors,” said\nRichard Peters, Chairman of the Board of Directors of Pharming. “Our\nimmediate priority is to ensure continuity across leadership, while\nmaintaining focus on the continued execution of Pharming’s strategy and its\ncommitment to patients.”\n\nFabrice Chouraqui added: “It has been a privilege to lead Pharming and to\nwork alongside colleagues who are deeply committed to improving the lives of\npeople with rare diseases. I have continually been inspired by the unwavering\npatient focus of our teams around the world and am deeply grateful for the\npassion and dedication they bring to our shared purpose every day. I leave\nwith great confidence in their ability to continue expanding Pharming’s\nimpact for patients and their families.”\n\nTo support an orderly transition process, Pharming and Mr. Chouraqui will not\ncomment further beyond this announcement. \n\nAbout Pharming\nPharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global\nbiotechnology company that develops and commercializes innovative medicines\nfor people living with rare immune and genetic diseases.\n\nWe combine specialized scientific, medical, regulatory and commercial\nexpertise to advance a focused portfolio of approved medicines and development\nprograms that address significant unmet medical needs. Guided by insights from\npatients and the wider rare disease community, we are dedicated to delivering\ninnovative therapies for some of the most challenging rare diseases.\n\nFor more information, visit www.pharming.com and find us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=cEBIILvCyiKshIdXO_U_E_vHSazAMbZTn-pkx3bZ4kOB-DCkBA2aL5NlKDFTRTCelOVM0iNXF8Wzc49OTfRAJxa1dSq34TK7ybX8sfyhuC0=).\n\nFor further public information, contact:\nPharming\nSaskia Mehring, Head of Corporate Communications \nT: +31 6 28 32 60 41 \nE: media.relations@pharming.com\n\nForward-looking Statements \nThis press release may contain forward-looking statements. Forward-looking\nstatements are statements of future expectations that are based on\nmanagement’s current expectations and assumptions and involve known and\nunknown risks and uncertainties that could cause actual results, performance,\nor events to differ materially from those expressed or implied in these\nstatements. These forward-looking statements are identified by their use of\nterms and phrases such as “aim”, “ambition”, ‘‘anticipate’’,\n‘‘believe’’, ‘‘could’’, ‘‘estimate’’,\n‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’,\n“milestones”, ‘‘objectives’’, ‘‘outlook’’,\n‘‘plan’’, ‘‘probably’’, ‘‘project’’,\n‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’,\n‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples\nof forward-looking statements may include statements with respect to timing\nand progress of Pharming's preclinical studies and clinical trials of its\nproduct candidates, Pharming's clinical and commercial prospects, and\nPharming's expectations regarding its projected working capital requirements\nand cash resources, which statements are subject to a number of risks,\nuncertainties and assumptions, including, but not limited to the scope,\nprogress and expansion of Pharming's clinical trials and ramifications for the\ncost thereof; and clinical, scientific, regulatory, commercial, competitive\nand technical developments. In light of these risks and uncertainties, and\nother risks and uncertainties that are described in Pharming's 2025 Annual\nReport and the Annual Report on Form 20-F for the year ended December 31,\n2025, filed with the U.S. Securities and Exchange Commission, the events and\ncircumstances discussed in such forward-looking statements may not occur, and\nPharming's actual results could differ materially and adversely from those\nanticipated or implied thereby. All forward-looking statements contained in\nthis press release are expressly qualified in their entirety by the cautionary\nstatements contained or referred to in this section. Readers should not place\nundue reliance on forward-looking statements. Any forward-looking statements\nspeak only as of the date of this press release and are based on information\navailable to Pharming as of the date of this release. Pharming does not\nundertake any obligation to publicly update or revise any forward-looking\nstatement as a result of new information, future events or other information.\n\nInside Information\nThis press release relates to the disclosure of information that qualifies, or\nmay have qualified, as inside information within the meaning of Article 7(1)\nof the EU Market Abuse Regulation.\n\nAttachment\n*     Pharming announces CEO transition_EN_29SEP2026\n(https://ml-eu.globenewswire.com/Resource/Download/796eba0c-facc-4b0d-b67b-18d8e11529af)","article_body_html":"","raw_payload":{"data":{"id":"nGNE6ThVP3-20260929","title":"REG-Pharming announces CEO transition","author":"Globe Newswire","ticker":"PHAR","created":"2026-09-29T05:00:00.176Z","tickers":["PHAR"],"exchange":"Euronext Amsterdam","article_body":"Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam:\nPHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune\nand genetic diseases, today announced that the Board of Directors and Fabrice\nChouraqui have mutually agreed that Mr. Chouraqui will step down as Chief\nExecutive Officer and Executive Director, with immediate effect.\n\nTo ensure continuity of leadership, the Board of Directors has appointed Mrs.\nLeverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief\nFinancial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will\nlead the patient-focused operations while Mr. Lynard will lead the global\ncorporate functions. The Board has started a formal search for a permanent\nsuccessor.\n\nFollowing discussions about the execution of Pharming's strategic priorities\nfor the next phase of the company, the Board of Directors and Mr. Chouraqui\nhave concluded that their views on how to advance the company's strategy are\nnot sufficiently aligned. In good consultation, the parties have therefore\nagreed on a leadership transition.\n\nPharming’s strategy, pipeline and commitment to patients remain unchanged.\nFocus remains on executing the strategic priorities and advancing the next\nphase of growth.\n\n“On behalf of the Board, I would like to express our appreciation for Mr.\nChouraqui’s contributions. We wish him well on his next endeavors,” said\nRichard Peters, Chairman of the Board of Directors of Pharming. “Our\nimmediate priority is to ensure continuity across leadership, while\nmaintaining focus on the continued execution of Pharming’s strategy and its\ncommitment to patients.”\n\nFabrice Chouraqui added: “It has been a privilege to lead Pharming and to\nwork alongside colleagues who are deeply committed to improving the lives of\npeople with rare diseases. I have continually been inspired by the unwavering\npatient focus of our teams around the world and am deeply grateful for the\npassion and dedication they bring to our shared purpose every day. I leave\nwith great confidence in their ability to continue expanding Pharming’s\nimpact for patients and their families.”\n\nTo support an orderly transition process, Pharming and Mr. Chouraqui will not\ncomment further beyond this announcement. \n\nAbout Pharming\nPharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global\nbiotechnology company that develops and commercializes innovative medicines\nfor people living with rare immune and genetic diseases.\n\nWe combine specialized scientific, medical, regulatory and commercial\nexpertise to advance a focused portfolio of approved medicines and development\nprograms that address significant unmet medical needs. Guided by insights from\npatients and the wider rare disease community, we are dedicated to delivering\ninnovative therapies for some of the most challenging rare diseases.\n\nFor more information, visit www.pharming.com and find us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=cEBIILvCyiKshIdXO_U_E_vHSazAMbZTn-pkx3bZ4kOB-DCkBA2aL5NlKDFTRTCelOVM0iNXF8Wzc49OTfRAJxa1dSq34TK7ybX8sfyhuC0=).\n\nFor further public information, contact:\nPharming\nSaskia Mehring, Head of Corporate Communications \nT: +31 6 28 32 60 41 \nE: media.relations@pharming.com\n\nForward-looking Statements \nThis press release may contain forward-looking statements. Forward-looking\nstatements are statements of future expectations that are based on\nmanagement’s current expectations and assumptions and involve known and\nunknown risks and uncertainties that could cause actual results, performance,\nor events to differ materially from those expressed or implied in these\nstatements. These forward-looking statements are identified by their use of\nterms and phrases such as “aim”, “ambition”, ‘‘anticipate’’,\n‘‘believe’’, ‘‘could’’, ‘‘estimate’’,\n‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’,\n“milestones”, ‘‘objectives’’, ‘‘outlook’’,\n‘‘plan’’, ‘‘probably’’, ‘‘project’’,\n‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’,\n‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples\nof forward-looking statements may include statements with respect to timing\nand progress of Pharming's preclinical studies and clinical trials of its\nproduct candidates, Pharming's clinical and commercial prospects, and\nPharming's expectations regarding its projected working capital requirements\nand cash resources, which statements are subject to a number of risks,\nuncertainties and assumptions, including, but not limited to the scope,\nprogress and expansion of Pharming's clinical trials and ramifications for the\ncost thereof; and clinical, scientific, regulatory, commercial, competitive\nand technical developments. In light of these risks and uncertainties, and\nother risks and uncertainties that are described in Pharming's 2025 Annual\nReport and the Annual Report on Form 20-F for the year ended December 31,\n2025, filed with the U.S. Securities and Exchange Commission, the events and\ncircumstances discussed in such forward-looking statements may not occur, and\nPharming's actual results could differ materially and adversely from those\nanticipated or implied thereby. All forward-looking statements contained in\nthis press release are expressly qualified in their entirety by the cautionary\nstatements contained or referred to in this section. Readers should not place\nundue reliance on forward-looking statements. Any forward-looking statements\nspeak only as of the date of this press release and are based on information\navailable to Pharming as of the date of this release. Pharming does not\nundertake any obligation to publicly update or revise any forward-looking\nstatement as a result of new information, future events or other information.\n\nInside Information\nThis press release relates to the disclosure of information that qualifies, or\nmay have qualified, as inside information within the meaning of Article 7(1)\nof the EU Market Abuse Regulation.\n\nAttachment\n*     Pharming announces CEO transition_EN_29SEP2026\n(https://ml-eu.globenewswire.com/Resource/Download/796eba0c-facc-4b0d-b67b-18d8e11529af)"},"type":"article","timestamp":"2026-09-29T05:00:00.2741773Z","server_sent_at_ms":1790658000274},"received_at":"2026-09-29T05:00:00.390Z","source_url":null},"analysis":{"id":"143493","press_release_id":"154736","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["CEO exit effective immediately with no permanent successor named","Departure driven by board/CEO strategic misalignment, signaling possible strategy tension ahead","Dual interim co-CEO structure may complicate decision-making during the search"],"eventType":"executive_change","narrative":"Pharming announced that CEO and Executive Director Fabrice Chouraqui has stepped down with immediate effect after the board concluded their views on the company's strategic direction were not sufficiently aligned.\n\nThe board appointed Chief Commercial Officer Leverne Marsh and CFO Kenneth Lynard as Interim Co-CEOs, splitting leadership between patient-focused operations and global corporate functions, and has begun a formal search for a permanent successor.\n\nThe company states its strategy, pipeline and patient commitments are unchanged, and Chairman Richard Peters emphasized continuity of execution during the transition.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"Surprise immediate CEO exit over strategy disagreement at Pharming -- watch for strategic drift or M&A speculation during the successor search."},"keyFigures":{},"quotedText":"the Board of Directors and Mr. Chouraqui have concluded that their views on how to advance the company's strategy are not sufficiently aligned","namedEntities":{"people":[{"name":"Fabrice Chouraqui","role":"Outgoing CEO and Executive Director"},{"name":"Leverne Marsh","role":"Interim Co-CEO, Chief Commercial Officer"},{"name":"Kenneth Lynard","role":"Interim Co-CEO, Chief Financial Officer"},{"name":"Richard Peters","role":"Chairman of the Board"}],"products":[],"companies":[{"name":"Pharming Group N.V.","ticker":"PHAR","relationship":"filer/issuer"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Immediate CEO departure with no permanent successor, driven by board-strategy misalignment, is a material leadership event. Mitigating factors: interim co-CEO structure named immediately and company states strategy/pipeline unchanged, so not a full score-5 shock."},"tickerRelevance":{"others":[{"ticker":"PHARM","relevance":"Euronext Amsterdam listing of same issuer"}],"primary":"PHAR"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"immediate CEO departure with interim co-CEOs","issuerAuthored":true,"continuityFactor":"strategy and pipeline stated unchanged"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"mixed","material_impact_score":4,"narrative":"Pharming announced that CEO and Executive Director Fabrice Chouraqui has stepped down with immediate effect after the board concluded their views on the company's strategic direction were not sufficiently aligned.\n\nThe board appointed Chief Commercial Officer Leverne Marsh and CFO Kenneth Lynard as Interim Co-CEOs, splitting leadership between patient-focused operations and global corporate functions, and has begun a formal search for a permanent successor.\n\nThe company states its strategy, pipeline and patient commitments are unchanged, and Chairman Richard Peters emphasized continuity of execution during the transition.","key_figures":{},"named_entities":{"people":[{"name":"Fabrice Chouraqui","role":"Outgoing CEO and Executive Director"},{"name":"Leverne Marsh","role":"Interim Co-CEO, Chief Commercial Officer"},{"name":"Kenneth Lynard","role":"Interim Co-CEO, Chief Financial Officer"},{"name":"Richard Peters","role":"Chairman of the Board"}],"products":[],"companies":[{"name":"Pharming Group N.V.","ticker":"PHAR","relationship":"filer/issuer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T05:00:08.035Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"immediate CEO departure with interim co-CEOs","issuerAuthored":true,"continuityFactor":"strategy and pipeline stated unchanged"}},"durationMs":7633,"modelName":"glm-5.3-flashx"}}